Forian Inc. Reports Significant Growth in Second Quarter 2025 Financial Results
TL;DR
Forian Inc. showcases a 56% revenue growth and a significant turnaround to net income, offering investors a competitive edge in the data science and analytics sector.
Forian Inc. reported Q2 2025 revenue of $7.5 million, a 56% increase from the previous year, with adjusted EBITDA rising to $0.6 million, reflecting operational efficiency and strategic growth.
Forian Inc.'s advancements in data science and analytics enhance healthcare and financial services, contributing to a more informed and efficient global healthcare ecosystem.
Discover how Forian Inc. turned a $2.6 million loss into a $0.2 million profit in just a year, showcasing remarkable financial resilience and strategic acumen.
Found this article helpful?
Share it with your network and spread the knowledge!
Forian Inc., a leader in data science-driven information and analytics solutions for the life science, healthcare, and financial services industries, has announced its financial results for the second quarter ended June 30, 2025. The company reported a significant 56% increase in revenue, reaching $7.5 million, up from $4.8 million in the same period last year. This growth is attributed to strategic contract renewals, new client acquisitions, and operational efficiencies.
The company also turned around its net income from a loss of $2.6 million in Q2 2024 to a profit of $0.2 million in Q2 2025. Adjusted EBITDA saw a dramatic increase to $0.6 million, compared to $0.1 million in the prior year, highlighting the company's improved profitability and margin expansion. Forian's cash, cash equivalents, and marketable securities stood strong at $35.6 million as of June 30, 2025.
Max Wygod, CEO and Executive Chairman of Forian, emphasized the company's continued execution and growth trajectory, focusing on both organic and strategic investments to enhance value across the healthcare ecosystem. The company has also reconfirmed its full-year 2025 outlook, expecting revenue to be between $28 to $30 million and Adjusted EBITDA to range from ($1.0) to $1.0 million.
Forian's performance this quarter underscores its ability to leverage its data science capabilities and proprietary analytics solutions to drive operational, clinical, and financial performance for its clients. The company's strategic deals and investments in data assets are expected to further strengthen its market position and offerings.
Investors and interested parties can access more information about Forian's financial results and future outlook through the company's website at https://www.forian.com/investors. The company will also host a conference call and webcast to discuss these results in detail, available at https://edge.media-server.com/mmc/p/76de8mny.
Curated from NewMediaWire
